<DOC>
	<DOC>NCT00819000</DOC>
	<brief_summary>The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.</brief_summary>
	<brief_title>Therapy Optimization in Multiple Sclerosis (MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Male or female, 18 years of age or older, with a diagnosis of MS. Being treated with Glatiramer Acetate (GA) or (IFN)β Receiving therapy from a participating Specialty Pharmacy Has any contraindication to GA or IFNβ therapy, including pregnancy, trying to become pregnant, or breast feeding during the study Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4aminopyridine or 4AP) Unlikely to be able to participate for the full two years of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Specialty Pharmacy</keyword>
	<keyword>Therapy Management</keyword>
	<keyword>Medication Compliance</keyword>
	<keyword>Medication Adherence</keyword>
	<keyword>Medication Persistence</keyword>
	<keyword>Health Outcomes</keyword>
</DOC>